Factors Associated With Use of Sipuleucel-T to Treat Patients With Advanced Prostate Cancer | Zendy

Megan E.V. Caram | Zendy; Ryan Ross | Zendy; Paul Lin | Zendy; Bhramar Mukherjee | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Factors Associated With Use of Sipuleucel-T to Treat Patients With Advanced Prostate Cancer

Author(s) -

Megan E.V. Caram,

Ryan Ross,

Paul Lin,

Bhramar Mukherjee

Publication year - 2019

Publication title -

jama network open

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.278

H-Index - 39

ISSN - 2574-3805

DOI - 10.1001/jamanetworkopen.2019.2589

Subject(s) - medicine , enzalutamide , prostate cancer , cabazitaxel , cohort , docetaxel , oncology , abiraterone acetate , asymptomatic , cancer , androgen deprivation therapy , androgen receptor

Key Points Question How is sipuleucel-T being used to treat patients with advanced prostate cancer, and what are the factors driving its use? Findings In this cohort study of 7272 patients treated for metastatic castration-resistant prostate cancer, 730 (10.0%) received sipuleucel-T. Factors such as a patient’s ethnicity, geographic region, income, and the specialty of the physician managing their treatment were associated with use of sipuleucel-T. Meaning Identifying disparities in receipt of sipuleucel-T may affect future access to this and other highly specialized cancer therapies by defining barriers to treatment that could be addressed in future studies.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research